Igm Biosciences Inc (IGMS)
$9.4
+1.75
(+22.88%)▲
Insights on Igm Biosciences Inc
Increasing Revenue
Revenue is up for the last 3 quarters, 448.0K → 651.0K (in $), with an average increase of 16.9% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -64.42M → -60.69M (in $), with an average increase of 3.0% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 82.2%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 328.1%
Performance
- $7.41$9.41$9.40
21.17%
Downside
Day's Volatility :21.25%
Upside
0.11%
- $3.81$17.70$9.40
59.47%
Downside
52 Weeks Volatility :78.47%
Upside
46.89%
Returns
| Period | Igm Biosciences Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -28.03% | 0.5% | 0.0% |
6 Months | 73.08% | 11.7% | 0.0% |
1 Year | -29.69% | 6.2% | 2.2% |
3 Years | -88.63% | 13.5% | -23.0% |
Highlights
Market Capitalization | 467.9M |
Book Value | $3.46 |
Earnings Per Share (EPS) | -4.71 |
Wall Street Target Price | 21.22 |
Profit Margin | 0.0% |
Operating Margin TTM | -9722.43% |
Return On Assets TTM | -34.91% |
Return On Equity TTM | -100.48% |
Revenue TTM | 2.1M |
Revenue Per Share TTM | 0.04 |
Quarterly Revenue Growth YOY | 75.0% |
Gross Profit TTM | 1.1M |
EBITDA | -253.4M |
Diluted Eps TTM | -4.71 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.21 |
EPS Estimate Next Year | -2.88 |
EPS Estimate Current Quarter | -1.03 |
EPS Estimate Next Quarter | -0.94 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 125.74%
Technicals Summary
Sell
Neutral
Buy
Igm Biosciences Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Igm Biosciences Inc | -11.87% | 73.08% | -29.69% | -88.63% | -68.52% |
 Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
 Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
 Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
 Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Igm Biosciences Inc | NA | NA | NA | -3.21 | -1.0 | -0.35 | NA | 3.46 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Igm Biosciences Inc | Buy | $467.9M | -68.52% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Institutional Holdings
Baker Bros Advisors LP
6.28%T. Rowe Price Associates, Inc.
5.55%Artal Group S A
5.27%Redmile Group, LLC
5.05%Goldman Sachs Group Inc
3.54%FMR Inc
2.89%
Corporate Announcements
Igm Biosciences Inc Earnings
Igm Biosciences Inc’s price-to-earnings ratio stands at None
Read More
Company Information
igm biosciences, inc., a biotechnology company, engages in the research and development of immunoglobulin m (igm) antibodies for the treatment of cancer. the company's lead product candidate is igm-2323, a bispecific igm antibody that is in phase 1 clinical trials to treat patients with b cell nhl and other b cell malignancies. it is also developing igm-8444, an igm antibody targeting death receptor 5 proteins; and igm-7354, is a bispecific igm antibody delivering interleukin-15 cytokines to pd-l1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. igm biosciences, inc. has a collaboration with atreca inc. and beigene ltd. to discover, develop, and manufacture novel igm and iga antibodies targeting sars-cov-2 for the potential treatment of covid-19; and strategic research collaboration and license agreement with abcellera to discover and develop igm antibodies. the company was formerly known as palingen, inc. and changed its name to igm biosci
Organization | Igm Biosciences Inc |
Employees | 224 |
CEO | Mr. Fred M. Schwarzer J.D. |
Industry | Health Technology |
